Juskaran Chadha

Juskaran Chadha practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Juskaran Chadha's NPI, 1689093320, was assigned on April 9, 2014. Juskaran Chadha graduated from New York Institute of Technology College of Osteopathic Medicine - Old Westbury in 2014. Juskaran Chadha holds Florida license OS16705.

Juskaran Chadha's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Juskaran Chadha's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Juskaran Chadha to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Juskaran Chadha practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Juskaran Chadha's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Juskaran Chadha is board certified in hematology by the American Board of Internal Medicine. Juskaran Chadha is licensed in Florida.

Dmand AI lists chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), lung cancer and prostate cancer among the conditions Juskaran Chadha treats.

CMS data shows 445 Medicare services from Juskaran Chadha across 2 procedure codes in 2024, all of them office visits, for 213 Medicare patients. Medicare paid $39,351 for them.

CMS counts 213 Medicare patients who saw Juskaran Chadha in 2024. The largest group is 65 to 74, with 117 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 2.24, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Juskaran Chadha's median patient age at 70, with 23% women.

In 2024, Juskaran Chadha wrote 911 Medicare Part D claims for 166 patients. 69% of them were for generic drugs. CMS names the drug for 775 of them, across 22 drugs with 11 or more claims each, at $3,042,771 in total drug cost. In 2023, CMS named 586 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Juskaran Chadha for performance year 2024, reported as part of a group. Juskaran Chadha accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Juskaran Chadha as offering telehealth.

Dmand AI links 20 papers to Juskaran Chadha, published from 2017 to 2025. 2023 was the busiest year, with 6. The most frequent topics are Carcinoma, Renal Cell, Kidney Neoplasms and Nivolumab. Juskaran Chadha has published most often in Cancers (Basel). Juskaran Chadha's most frequent co-authors are Jad Chahoud, MD, Philippe E. Spiess, MD and Filip Ionescu, MD.

CMS Open Payments shows 41 general payments to Juskaran Chadha from 11 drug and device companies from 2018 to 2025. Travel and lodging make up the largest share, 48% of the total. Exelixis Inc. paid the most, $1,944.

Juskaran Chadha graduated from New York Institute of Technology College of Osteopathic Medicine - Old Westbury in 2014. Juskaran Chadha is a member of ACP, ASCO and ASH.

Juskaran Chadha is in network with 11 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.